Tositumomab
From Proteopedia
proteopedia linkproteopedia link Pharmacokinetics
| Anti-CD20 Monoclonal Antibody Pharmacokinetics [1]
|
| Parameter
| Tositumomab
| Ofatumumab
| Rituximab
| Ibritumomab
|
| Tmax (hr)
| Tositumomab
| 7.6
| Rituximab
| Ibritumomab
|
| Cmax (ng/ml)
| Tositumomab
| 167000
| 205800
| 67000
|
| Bioavailability (%)
| Tositumomab
| Ofatumumab
| Rituximab
| Ibritumomab
|
| T1/2 (hr)
| 64.8
| 68
| 206
| 108
|
| AUC (ng/ml/hr)
| Tositumomab
| 32939000
| Rituximab
| 17000
|
| Clearance (L/h)
| .078
| .017
| .009
| Ibritumomab
|
| IC50 (nM)
| Tositumomab
| Ofatumumab
| Rituximab
| Ibritumomab
|
| Dosage
| Tositumomab
| 500 mg (4th Infusion)
| 325 mg/m2 (4th Infusion)
| Ibritumomab
|
| Metabolism
| Tositumomab
| Ofatumumab
| Rituximab
| Ibritumomab
|
